跳转至内容
Merck
CN
  • Successful closure of gastrocutaneous fistulas using the Surgisis(®) anal fistula plug.

Successful closure of gastrocutaneous fistulas using the Surgisis(®) anal fistula plug.

Annals of the Royal College of Surgeons of England (2014-05-02)
J H Darrien, H Kasem
摘要

Gastrocutaneous fistulas remain an uncommon complication of upper gastrointestinal surgery. Less common but equally problematic are gastrocutaneous fistulas secondary to non-healing gastrostomies. Both are associated with considerable morbidity and mortality. Surgical repair remains the gold standard of care. For those unfit for surgical intervention, results from conservative management can be disappointing. We describe a case series of seven patients with gastrocutaneous fistulas who were unfit for surgical intervention. These patients were managed successfully in a minimally invasive manner using the Surgisis(®) (Cook Surgical, Bloomington, IN, US) anal fistula plug. Between September 2008 and January 2009, seven patients with gastrocutaneous fistulas presented to Wishaw General Hospital. Four gastrocutaneous fistulas represented non-healing gastrostomies, two followed an anastomotic leak after an oesophagectomy and one following an anastomotic leak after a distal gastrectomy. All patients had poor nutritional reserve with no other identifiable reason for failure to heal. All were deemed unfit for surgical intervention. Five gastrocutaneous fistulas were closed successfully using the Surgisis(®) anal fistula plug positioned directly into the fistula tract under local anaesthesia and two gastrocutaneous fistulas were closed successfully using the Surgisis(®) anal fistula positioned endoscopically using a rendezvous technique. For the five patients with gastrocutaneous fistulas closed directly under local anaesthesia, oral alimentation was reinstated immediately. Fistula output ceased on day 12 with complete epithelialisation occurring at a median of day 26. For the two gastrocutaneous fistulas closed endoscopically using the rendezvous technique, oral alimentation was reinstated on day 5 with immediate cessation of fistula output. Follow-up upper gastrointestinal endoscopy confirmed re-epithelialisation at eight weeks. In none of the cases has there been fistula recurrence (range of follow-up duration: 30-59 months). Surgisis(®) anal fistula plugs can be used safely and effectively to close gastrocutaneous fistulas in a minimally invasive manner in patients unfit for surgical intervention.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type IV, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
I型胶原蛋白 溶液 来源于大鼠尾, BioReagent, suitable for cell culture, sterile-filtered
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type IV, powder
Sigma-Aldrich
胶原蛋白 来源于大鼠尾, Bornstein and Traub Type I, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于鸡胸软骨, Type II (Miller), powder, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于小牛皮, Bornstein and Traub Type I, (0.1% solution in 0.1 M acetic acid), aseptically processed, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白IV型 来源于人类细胞培养基, Bornstein and Traub Type IV, 0.3 mg/mL, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type I (Sigma Type VIII), powder
Sigma-Aldrich
胶原 人, Bornstein and Traub Type I, acid soluble, powder, ~95% (SDS-PAGE)
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type III (Sigma Type X), powder
Sigma-Aldrich
胶原蛋白 来源于 Engelbreth-Holm-Swarm 小鼠肉瘤基底膜, Type IV (Miller), lyophilized powder, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type IV, solution, suitable for cell culture, High Performance
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type V (Sigma Type IX), powder
Sigma-Aldrich
胶原 来源于人类胎盘, Bornstein and Traub Type IV, powder